Fourth Circuit Says CMS’ Definition of “Line-Extension” Drug Is Consistent with Medicaid Rebate Statute
- April 12, 2024
The expansive regulatory definitions of “line-extension” drug and “new formulation” lines were not contrary to the Medicaid statute for purposes of determining rebates drug manufacturers may owe the program, the Fourth Circuit held April 10.
ARTICLE TAGS
You must be logged in to access this content.